Clik here to view.
Engine Biosciences Secures $27 Million Series A Extension to Advance...
SINGAPORE & REDWOOD CITY, Calif. Engine Biosciences, a company leveraging machine learning and high-throughput biology to discover and develop precision oncology medicines, today announced the...
View ArticleClik here to view.
EpimAb Biotherapeutics to Present a Late-Breaking Abstract of First-in-Human...
SHANGHAI EpimAb Biotherapeutics, a clinical stage biotechnology company specializing in the development of bispecific antibodies, is excited to announce that the company will present the...
View ArticleClik here to view.
Genome Insight Secures $23 Million in Series B-2 Funding Round
SAN DIEGO Genome Insight, a precision healthcare solutions company promoting whole-genome technology for accurate diagnosis and personalized treatment for cancer and rare disease, today announced...
View ArticleClik here to view.
Presentations at MPN Congress and ASH Annual Meeting Reinforce Clinical Role...
BURLINGTON, Mass. PharmaEssentia USA Corporation, a subsidiary of PharmaEssentia Corporation (TPEx:6446), a global biopharmaceutical innovator based in Taiwan leveraging deep expertise and proven...
View ArticleClik here to view.
Dizal Highlights Its Advances in Hematological Portfolio at 2023 ASH,...
SHANGHAI Dizal today announced that it will have four presentations from its hematological oncology pipeline, including golidocitinib and DZD8586, at the 65th American Society of Hematology Annual...
View ArticleClik here to view.
开创健康老龄科学的未来：Timeline® 举办首届全球尿石素A峰会并提供全天虚拟体验
瑞士洛桑 (美国商业资讯)– 由Timeline 定于11月7日主办的首届全球尿石素A科学峰会将介绍长寿研究领域的颠覆性研究成果。本次虚拟峰会由科学界专家主导，并向公众、从业者和科学家开放，将重点介绍衰老方面的最新研究，并特别聚焦尿石素A这一对健康有实质影响的突破性后生元天然分子。 本次峰会将探索有关尿石素A的最新科研成果，届时将有多位杰出研究者和临床医师参加，包括Johan...
View ArticleClik here to view.
ヘルシーエイジング科学の未来を切り拓くータイムライン®、1日のバーチャル体験となる初のグローバル・ウロリチンA・サミット開催へ
スイス、ローザンヌ （ビジネスワイヤ） —...
View ArticleClik here to view.
Clik here to view.
LegoChem Biosciences Selects BostonGene as Genomic Partner for First-in-Human...
WALTHAM, Mass. BostonGene, a leading provider of AI-driven, molecular and immune profiling solutions, and LegoChem Biosciences, Inc. (LCB), a clinical-stage biopharmaceutical company developing...
View ArticleClik here to view.
Crown Bioscience Introduces OrganoidXplore: Revolutionizing Cancer Research...
SAN DIEGO Crown Bioscience, a global contract research organization (CRO) and JSR Life Sciences company, today announced the launch of its ground-breaking service offering, OrganoidXploreTM. This...
View ArticleClik here to view.
Menarini Group and SciClone Pharmaceuticals Announce Exclusive Sub-Licensing...
FLORENCE, Italy & HONG KONG The Menarini Group (“Menarini”), a leading international pharmaceutical and diagnostics company, and SciClone Pharmaceuticals (Holdings) Ltd. (“SciClone”), an...
View ArticleClik here to view.
Mary Kay Ash Foundation℠ Celebrates Five Years Shaping the Future of Cancer...
DALLAS The Mary Kay Ash Foundation℠, a decades-long leader and advocate for finding cures for cancers affecting women, and UT Southwestern Medical Center, one of the nation’s premier academic...
View ArticleClik here to view.
AdvanCell Announces First Patient Dosed in Phase I/II TheraPb Clinical Trial...
SYDNEY AdvanCell, a radiopharmaceutical company developing a pipeline of Targeted Alpha Therapies for cancer patients, today announced the first patient was treated with 212Pb-ADVC001, a Targeted...
View ArticleClik here to view.
Mary Kay Ash基金会℠ 与德克萨斯大学西南医学中心历时五年，联手开创癌症研究新未来
达拉斯 (美国商业资讯)– Mary Kay Ash基金会℠数十年来一直是女性癌症治疗的领导者与倡导者。该基金会与位于德克萨斯州达拉斯的德克萨斯大学西南医学中心(UT Southwestern Medical Center)这一美国顶级学术性医疗中心共同庆祝国际癌症研究博士后学者奖学金计划五年来的合作成果。该计划由德克萨斯大学西南医学中心的Harold C....
View ArticleClik here to view.
Crown BioscienceがOrganoidXploreを発表：高速大規模オルガノイド創薬スクリーニングでがん研究に革命を起こす
米国サンディエゴ （ビジネスワイヤ） — 世界的な医薬品開発業務受託機関（CRO）であるCrown...
View ArticleClik here to view.
BeiGene to Present at the Jefferies London Healthcare Conference
BASEL, Switzerland & BEIJING & CAMBRIDGE, Mass. BeiGene, Ltd. (NASDAQ: BGNE; HKEX: 06160; SSE: 688235), a global biotechnology company, today announced that the Company will participate in...
View ArticleClik here to view.
Clik here to view.
Takeda Receives U.S. FDA Approval of FRUZAQLA™ (fruquintinib) for Previously...
OSAKA, Japan & CAMBRIDGE, Mass. Takeda (TSE:4502/NYSE:TAK) today announced that the U.S. Food and Drug Administration (FDA) has approved FRUZAQLA™ (fruquintinib), an oral targeted therapy for...
View ArticleClik here to view.
VANFLYTA® Approved in the EU as the First FLT3 Inhibitor Specifically for...
TOKYO & MUNICH Daiichi Sankyo’s (TSE: 4568) VANFLYTA® (quizartinib) has been approved in the European Union (EU) for use in combination with standard cytarabine and anthracycline induction and...
View ArticleClik here to view.
GenScript ProBio Partners With NuclixBio to Pave the Way for South Korea’s...
SEOUL, Korea GenScript ProBio, a global multimodality CDMO and NuclixBio, a company developing treatments based on circular RNA, announced on 9th Nov that they have entered into a strategic business...
View Article